<DOC>
	<DOC>NCT01371474</DOC>
	<brief_summary>The objective of this survey was to understand the safety and efficacy of PAXIL tablets ("PAXIL", hereinafter) when it was started at 20 mg/day in subjects with depression or in a depressed state.</brief_summary>
	<brief_title>Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg/Day)</brief_title>
	<detailed_description />
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Patients with depression or in a depressed state Patients who start taking paroxetine at 20mg a day Patients who have been treated with paroxetine prior to this investigation Patients with hypersensitivity to paroxetine Patients taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs Concomitant use in patients taking pimozide</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>